Meanwhile, the last five years have been challenging for investors in GlaxoSmithKline ( LSE: GSK ). It has been embroiled in controversy regarding alleged bribery and has failed to rejuvenate its product offering, with the consequence being that sales and profitability have come under severe pressure. As a result, GlaxoSmithKline's share price has risen by just 15% since August 2010, which is a small fraction of the performance of Smith & Nephew and Hikma during the same period.